Collegium Pharmaceutical (COLL) Cash from Investing Activities (2015 - 2026)

Collegium Pharmaceutical's Cash from Investing Activities history runs 12 years deep, the most recent figure standing at $1.6 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 116.81% year-over-year to $1.6 million; the TTM figure through Mar 2026 stood at -$52.2 million (up 81.3% YoY), while the FY2025 annual figure was -$63.5 million, up 77.92% from the prior year.
• Cash from Investing Activities was $1.6 million for Q1 2026 at Collegium Pharmaceutical, up from -$20.1 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $1.6 million in Q1 2026 to a low of -$572.2 million in Q1 2022.
• Historically, Cash from Investing Activities has averaged -$58.5 million across 5 years, with a median of -$9.7 million in 2025.
• The sharpest annual moves came in 2022 and 2026: Cash from Investing Activities tumbled 133586.21% in 2022, then surged 116.81% in 2026.
• A 5-year view of Cash from Investing Activities shows it stood at -$940000.0 in 2022, then slumped by 2569.89% to -$25.1 million in 2023, then surged by 53.13% to -$11.8 million in 2024, then sank by 70.63% to -$20.1 million in 2025, then jumped by 108.11% to $1.6 million in 2026.
• The last three Cash from Investing Activities figures came in at $1.6 million (Q1 2026), -$20.1 million (Q4 2025), and -$30.9 million (Q3 2025), per Business Quant data.